Nevertheless, the efficacy and safety profile of IL-17-targeting approaches remains controversial in regards of IBD as secukinumab, a human anti-IL-17A monoclonal antibody, has been reported to be a potential trigger of intestinal mucosal inflammation when being used in the treatment of other IMIDs such as in ankylosing spondylitis or psoriatic arthritis patients [187,188]. Here, IL17A is linked to ankylosing spondylitis.